Anti-TROP2 Antibody, clone TrMab-29

Quality Control Testing

Evaluated by Western Blotting in lysate from CHO-K1 cells overexpressing TROP2.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected TROP2 in lysate from CHO-K1 cells overexpressing TROP2

Tested Applications

Immunohistochemistry (Paraffin) Analysis: A representative lot detected TROP2 in Immunohistochemistry applications (Sayama, Y., et al. (2021). Biochem Biophys Rep. 25: 100902).

Western Blotting Analysis: A representative lot detected TROP2 in Western Blotting applications (Sayama, Y., et al. (2021). Biochem Biophys Rep. 25: 100902).

Flow Cytometry Analysis: A representative lot detected TROP2 in Flow Cytometry applications (Sayama, Y., et al. (2021). Biochem Biophys Rep. 25: 100902).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-TROP2, clone TrMab-29, Cat. No. MABS2310, is a mouse monoclonal antibody that detects TROP2 and is tested for use in Flow Cytometry, Immunohistochemistry, and Western Blotting.

Clone TrMab-29 is a mouse monoclonal antibody that detects Tumor-associated calcium signal transducer 2 TROP2).

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Tumor-associated calcium signal transducer 2 (UniProt: P09758; also known as Cell surface glycoprotein Trop-2, Trophoblast antigen 2, Membrane component chromosome 1 surface marker 1, Pancreatic carcinoma marker protein GA733-1) is encoded by the TACSTD2 (also known as GA733-1, M1S1, TROP2) gene (Gene ID: 4070) in human. TROP2 is a single-pass type 1 membrane glycoprotein that is synthesized with a signal peptide (aa 1-26), which is subsequently cleaved off to generate the mature form that contains an extracellular domain (aa 27-274), a transmembrane domain (aa 275-297), and a cytoplasmic domain (aa 298-323). It contains both extracellular epidermal growth factor-like and thyroglobulin type-1 repeat domains. Its expression is observed in placenta and is highly expressed in many cancers where it plays a role in tumor progression. About 85% of all solid cancers display increased expression of TROP2. Its expression is also reported in stem cells in various tissues. TROP2 expression in cancer cells has been correlated with drug resistance. Upregulation of TROP2 is reported to drive the expression and activation of CREB1, Jun, NF-kB, Rb, STAT1, and STAT3 through induction of the cyclin D1 and the ERK pathways. Mutations in TACSTD2 is known to cause corneal dystrophy of the gelatinous drop-like type (GDLD), an autosomal recessive disorder that is characterized by pathognomonic branching lattice figures in the cornea leading to blindness. (Ref.: Sayama, Y., et al. (2021). Biochem. Biophys. Rep. 25; 100902; Anna Shvartsur, A., and Bonavida, B. (2015). Genes Cancer. 6(3-4); 84-105).

CHO K1 cells overexpressing TROP2-PA and PA-TROP2-RAP-MAP.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Recommended storage: +2°C to +8°C.